| AASLD

Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum

Read more about Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum

Xuehua Piao, Soh Yamazaki, Sachiko Komazawa‐Sakon, Sanae Miyake, Osamu Nakabayashi, Takeyuki Kurosawa, Tetsuo Mikami, Minoru Tanaka, Nico Van Rooijen, Masaki Ohmuraya, Akira Oikawa, Yuko Kojima, Soichiro Kakuta, Yasuo Uchiyama, Masato Tanaka, Hiroyasu Nakano – 22 October 2016 – Tissue‐resident macrophages and bone marrow (BM)‐derived monocytes play a crucial role in the maintenance of tissue homeostasis; however, their contribution to recovery from acute tissue injury is not fully understood.

Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST‐C study

Read more about Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST‐C study

Joanne E. Brady, Danielle K. Liffmann, Anthony Yartel, Natalie Kil, Alex D. Federman, Joseph Kannry, Cynthia Jordan, Omar I. Massoud, David R. Nerenz, Kimberly A. Brown, Bryce D. Smith, Claudia Vellozzi, David B.

Antiviral treatment and liver‐related complications in hepatitis delta

Read more about Antiviral treatment and liver‐related complications in hepatitis delta

Anika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Patrick Lehmann, Svenja Hardtke, Katja Deterding, Kerstin Port, Max Westphal, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 22 October 2016 – Hepatitis delta virus (HDV) is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG‐IFNα) is effective in only 25%‐30% of patients and is associated with frequent side effects. The aim of this study was to analyze the clinical long‐term outcome of hepatitis delta in relation to different antiviral treatment strategies.